CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have given CAMP4 Therapeutics Corporation (NASDAQ:CAMP) an average recommendation of "Moderate Buy," with seven analysts recommending a buy and two a sell. The average 12-month price target is $8.36, significantly higher than the current share price of $4.22. Recent actions include an upgrade …